Merck (MRK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Merck & Co., Inc. (NYSE ... The company also secured a $2 billion licensing deal with Chinese drugmaker Hansoh Pharma in December 2024 for an experimental weight loss pill. This strategic move ...

Merck (MRK) signed a licensing agreement with Chinese biotech company Hansoh Pharma (3692.HK) for its oral GLP-1 weigh-loss drug is valued as high as $2 billion. To watch more expert insights and ...

AbbVie ABBV announced that it has entered into a licensing agreement with Denmark-based biotech Gubra for the latter’s ...

Atomwise is already working with some of the biggest names in pharma and medicine, including Merck & Co, Eli Lilly, and AbbVie. In 2019 they struck a major deal with China's Hansoh pharmaceuticals.

This coincided with another ADC deal potentially worth more than $1.5 billion from GSK, which licensed in an early stage ovarian and endometrial cancer drug, HS-20089, from Hansoh Pharma.

With increasing biomarker-driven cancer treatments, TEPMETKO benefits from growing adoption in precision oncology. Competition from other MET inhibitors like TABRECTA (capmatinib) exists, but ...

The largest oncology licensing deal was Merck & Co. Inc.’s transaction for global rights to LaNova Medicines’ vascular endothelial growth factor (VEGF)‒programmed cell death protein-1 (PD-1 ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...